neurocrine bios - NBIX
NBIX
Close Chg Chg %
100.68 1.06 1.05%
Closed Market
101.74
+1.06 (1.05%)
Volume: 1.59M
Last Updated:
Apr 22, 2025, 4:00 PM EDT
Company Overview: neurocrine bios - NBIX
NBIX Key Data
| Open $101.48 | Day Range 100.83 - 102.67 |
| 52 Week Range 84.23 - 157.98 | Market Cap $9.96B |
| Shares Outstanding 98.94M | Public Float 96.05M |
| Beta 0.33 | Rev. Per Employee N/A |
| P/E Ratio 30.59 | EPS $3.39 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.73M |
NBIX Performance
| 1 Week | 0.36% | ||
| 1 Month | -9.10% | ||
| 3 Months | -31.59% | ||
| 1 Year | -25.19% | ||
| 5 Years | 3.63% |
NBIX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About neurocrine bios - NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
NBIX At a Glance
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
San Diego, California 92130
| Phone | 1-858-617-7600 | Revenue | 2.36B | |
| Industry | Biotechnology | Net Income | 341.30M | |
| Sector | Health Technology | 2024 Sales Growth | 24.811% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,800 | |
| View SEC Filings |
NBIX Valuation
| P/E Current | 30.591 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 41.474 |
| Price to Sales Ratio | 6.01 |
| Price to Book Ratio | 5.239 |
| Price to Cash Flow Ratio | 23.774 |
| Enterprise Value to EBITDA | 21.751 |
| Enterprise Value to Sales | 5.763 |
| Total Debt to Enterprise Value | 0.037 |
NBIX Efficiency
| Revenue/Employee | 1,308,500.00 |
| Income Per Employee | 189,611.111 |
| Receivables Turnover | 4.916 |
| Total Asset Turnover | 0.656 |
NBIX Liquidity
| Current Ratio | 3.397 |
| Quick Ratio | 3.284 |
| Cash Ratio | 2.12 |
NBIX Profitability
| Gross Margin | 97.559 |
| Operating Margin | 25.347 |
| Pretax Margin | 20.634 |
| Net Margin | 14.491 |
| Return on Assets | 9.511 |
| Return on Equity | 14.157 |
| Return on Total Capital | 11.062 |
| Return on Invested Capital | 12.332 |
NBIX Capital Structure
| Total Debt to Total Equity | 19.141 |
| Total Debt to Total Capital | 16.066 |
| Total Debt to Total Assets | 12.885 |
| Long-Term Debt to Equity | 17.573 |
| Long-Term Debt to Total Capital | 14.75 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Neurocrine Bios - NBIX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.13B | 1.49B | 1.89B | 2.36B | |
Sales Growth
| +8.38% | +31.34% | +26.76% | +24.81% | |
Cost of Goods Sold (COGS) incl D&A
| 25.20M | 38.30M | 57.50M | 57.50M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.90M | 15.60M | 21.30M | 27.10M | |
Depreciation
| 10.90M | 15.10M | 17.80M | 23.50M | |
Amortization of Intangibles
| - | 500.00K | 3.50M | 3.60M | |
COGS Growth
| - | +34.76% | +51.98% | +50.13% | |
Gross Income
| 1.11B | 1.45B | 1.83B | 2.30B | |
Gross Income Growth
| +7.90% | +30.87% | +26.14% | +25.59% | |
Gross Profit Margin
| +97.78% | +97.43% | +96.95% | +97.56% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 900.50M | 1.20B | 1.43B | 1.70B | |
Research & Development
| 317.20M | 448.70M | 547.20M | 707.60M | |
Other SG&A
| 583.30M | 751.00M | 887.60M | 993.20M | |
SGA Growth
| +28.70% | +33.23% | +19.60% | +18.54% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 84.40M | 40.90M | 115.50M | 75.40M | |
EBIT after Unusual Expense
| 123.40M | 209.80M | 279.30M | 521.60M | |
Non Operating Income/Expense
| 3.80M | 11.20M | 57.40M | 91.00M | |
Non-Operating Interest Income
| 3.80M | 11.20M | 57.40M | 91.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 25.80M | 7.10M | 4.60M | 126.60M | |
Interest Expense Growth
| -21.34% | -72.48% | -35.21% | +2,652.17% | |
Gross Interest Expense
| 25.80M | 7.10M | 4.60M | 126.60M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 101.40M | 213.90M | 332.10M | 486.00M | |
Pretax Income Growth
| -4.97% | +110.95% | +55.26% | +46.34% | |
Pretax Margin
| +8.95% | +14.37% | +17.60% | +20.63% | |
Income Tax
| 11.80M | 59.40M | 82.40M | 144.70M | |
Income Tax - Current - Domestic
| 6.30M | 37.40M | 143.10M | 267.70M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 5.50M | 22.00M | (60.70M) | (123.00M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 89.60M | 154.50M | 249.70M | 341.30M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 89.60M | 154.50M | 249.70M | 341.30M | |
Net Income Growth
| -78.00% | +72.43% | +61.62% | +36.68% | |
Net Margin Growth
| +7.90% | +10.38% | +13.23% | +14.49% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 89.60M | 154.50M | 249.70M | 341.30M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 89.60M | 154.50M | 249.70M | 341.30M | |
EPS (Basic)
| 0.9472 | 1.6127 | 2.5558 | 3.3994 | |
EPS (Basic) Growth
| -78.35% | +70.26% | +58.48% | +33.01% | |
Basic Shares Outstanding
| 94.60M | 95.80M | 97.70M | 100.40M | |
EPS (Diluted)
| 0.9152 | 1.5622 | 2.4723 | 3.2912 | |
EPS (Diluted) Growth
| -78.02% | +70.69% | +58.26% | +33.12% | |
Diluted Shares Outstanding
| 97.90M | 98.90M | 101.00M | 103.70M | |
EBITDA
| 218.70M | 266.30M | 416.10M | 624.10M | |
EBITDA Growth
| -34.93% | +21.76% | +56.25% | +49.99% | |
EBITDA Margin
| +19.29% | +17.89% | +22.05% | +26.50% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 158.75 | |
| Number of Ratings | 27 | Current Quarters Estimate | 0.912 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 4.057 | |
| Last Quarter’s Earnings | 0.756 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.29 | Next Fiscal Year Estimate | 6.10 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 18 | 18 | 19 | 16 |
| Mean Estimate | 0.91 | 1.23 | 4.06 | 6.10 |
| High Estimates | 1.37 | 1.60 | 5.90 | 7.73 |
| Low Estimate | 0.21 | 0.68 | 2.54 | 3.67 |
| Coefficient of Variance | 27.86 | 18.16 | 20.37 | 19.57 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 20 | 19 | 19 |
| OVERWEIGHT | 2 | 3 | 4 |
| HOLD | 5 | 6 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Overweight | Buy |
SEC Filings for Neurocrine Bios - NBIX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Neurocrine Bios - NBIX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 17, 2025 | Kevin Charles Gorman Director | 527,221 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 7,169 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 38,252 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 43,405 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.75 per share | 5,067,533.75 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 44,491 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 42,474 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.76 per share | 4,959,264.24 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 43,572 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 41,489 | Bona fide gift | 0.00 |
| Feb 17, 2025 | Kevin Charles Gorman Director | 16,812 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Kevin Charles Gorman Director | 10,754 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Kevin Charles Gorman Director | 524,209 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.68 per share | 61,164,706.12 |
| Feb 17, 2025 | Stephen A. Sherwin Director | 10,673 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.69 per share | 1,245,432.37 |
| Feb 17, 2025 | Kevin Charles Gorman Director | 521,618 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.69 per share | 60,867,604.42 |
| Feb 17, 2025 | Kevin Charles Gorman Director | 524,450 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 4,166 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Darin Michael Lippoldt Chief Legal Officer | 6,053 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Ingrid Delaet Chief Regulatory Officer | 4,203 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Julie S. Cooke Chief Human Resources Officer | 19,544 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.77 per share | 2,282,152.88 |
| Feb 17, 2025 | Julie S. Cooke Chief Human Resources Officer | 20,945 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Julie S. Cooke Chief Human Resources Officer | 20,190 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.8 per share | 2,358,192.00 |